Investor Presentaiton
MAX
Healthcare
Demonstrated best in class financial performance in last two
fiscals
Gross Revenue (INR Cr)
3,920
(11%
4,356
Sharp recovery post Covid-19 impact
EBITDA (¹) (INR Cr)
590
515
360
348
2,320
1,561
49%
70%
1,385
1,161
263
37%
121
19%
326%)
FY19
FY20
H1FY21
H2FY21
Q4FY21 Q1FY22
FY19
FY20
H1FY21
H2FY21
Q4FY21 Q1FY22
Margin (2) (INR Cr)
9.7%
(5.0%
14.7%
8.3%
(15.4%
27.2%
(3.1%)
23.7%
24.1%
וי
FY19
FY20
H1FY21
H2FY21
Q4FY21
Q1FY22
.
•
•
Q1 FY22 gross revenue at INR 1,385 Cr versus INR 1,161 Cr in Q4 FY21
(+19% QoQ). This includes revenue of INR 136 Cr from Covid-19
vaccination and related antibody tests post inoculation
Operating EBITDA for Q1 FY22 was highest ever for 3rd consecutive
quarter at INR 360 Cr versus INR 263 Cr in Q4 FY21 (+37% QoQ)
Margin expansion was driven by high overall occupancy, significant
uptake in Covid-19 vaccine administration, underpinned by impact of
augmentation of clinical programs and structural cost initiatives
implemented during FY20 and FY21
(1) EBITDA excludes one-time transaction costs of INR 37 Cr in FY19, INR 43 Cr in FY20 and INR 48 Cr in FY21; Numbers are post IND AS 116 | (2) Margin calculated on Net Revenue
26View entire presentation